Protein Expression Market Size, Share & Trends Analysis Report By Expression System (Prokaryotic, Mammalian Cell), By Product (Reagents, Services), By Application, By End-user- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Protein Expression market size was estimated at USD 3.8 billion in 2022 and is projected to hit around USD 6.18 billion by 2030, growing at a CAGR of 10.32% during the forecast period 2022 to 2030.

Key Takeaways:

• By Expression System, the U.S. Protein Expression market was valued at USD 980 million in 2021 and expected to witness growth at a CAGR of 8.9% from 2022 to 2030.
• By expression system, the prokaryotic segment accounted for the largest share in 2021. The high usage of this system among the researchers is due to enabling them to produce biologically active proteins in large quantities in a short time
• By product, the services segment is anticipated to witness lucrative growth over the forecast period. The increasing outsourcing to CROs and growing demand for recombinant protein in the non-healthcare sectors are fueling the segment growth
• By application, the therapeutic segment dominated the market in 2021. This is attributed to an increase in R&D investment and strategic initiatives such as fundraising
• By end-user, the pharmaceutical and biotechnological companies segment held the largest revenue share in 2021 owing to the growing demand for biologics for chronic diseases
• North America dominated the global market in 2021 owing to the availability of funding opportunities for emerging players, along with the existence of significant R&D investment in the region

The increasing research in proteomics and genomics, the rising incidence of chronic diseases, and escalating demand for biologic products around the globe are enhancing the demand for protein expression, which is likely to drive the market. For instance, in April 2022, in a research published on Frontiers Media S.A., researchers differentially expressed 22 proteins to identify potential diagnostic biomarkers for Multiple Sclerosis (MS).

An increase in R&D investments by the players is estimated to have a considerable impact on the usage of protein expression. In August 2022, the managing director of Biocon Biologics stated in one of his interviews that the overall cost of the R&D is 12-14% of revenues. The investment is essential to build a sustainable portfolio of around 20 biosimilar molecules and the company is anticipated to launch at least once every 1-2 years. The approximate cost of developing these molecules is USD 50-100 million.

Other determinants such as rapid acceleration in the demand for protein therapeutics and government investment in the applications of the protein expression industry are also supporting the market growth. For instance, in May 2022, Proteomics International Laboratories was awarded approximately USD 286,833 funding from the Australian Government under the Medical Research Future Fund (MRFF) initiative. The funding is expected to support the manufacturing of the PromarkerD test in Australia. Such financial assistances are likely to supplement the market growth in the coming years.

The outbreak of the COVID-19 pandemic developed the urge to profile and conduct differential gene expression analyses on COVID-19 patients. Research published in Briefings in Bioinformatics, March 2021, employed the data of protein-drug interaction to identify the prospective drugs for COVID-19. As a result, the usage of the process is projected to upsurge during the COVID-19 pandemic and contribute to market growth.

The growing requirement for personalized therapy and vaccine is expected to be the key factor fueling the market growth during the forecast period. For instance, in January 2022, Amgen announced a collaboration with Generate Biomedicines to discover and develop protein therapeutics for various areas. The companies are estimating the worth of this collaboration around USD 1.9 billion.

The increasing development of recombinant proteins for industrial use, such as the production of food and beverages, is anticipated to boost the use of protein expression in the non-healthcare sector. However, the retail pricings of recombinant proteins for industrial and pharmaceutical uses are drastically different as pharmaceutical proteins are sold for billions of dollars per kg, while industrial proteins for tens of dollars per kg. R&D, clinical trials, and patents are the additional requirements of pharmaceutical proteins. 

Report Scope of the Protein Expression Market

Expression System Insights

The prokaryotic segment held the largest share of over 41.9% in 2022 as it is relatively easier to handle and fulfill major purposes in research. The segment is anticipated to maintain its position in the forecast period owing to favorable characteristics, such as large-scale recombinant protein production in a short time and at a lower cost.

The mammalian cell segment is projected to grow at the fastest rate during the forecast period. Various pharmaceutical companies have employed mammalian expression systems to develop and produce proteins transiently or through stable cell lines. This takes place where particular expression constructs combine into the genome host. However, the employment of systems depends on the purpose and approach. For instance, for antigen production, structural studies, and activity studies, wherein post-translational is not a requirement, the prokaryotic is considered to be ideal. However, companies prefer mammalian cells for the production of vaccines, therapeutics, and proteins.

Product Insights

Reagents dominated the market with a revenue share of over 41.9% in 2021. The market consists of mature players such as Agilent Technologies, Inc. and Thermo Fisher Scientific. The companies offer a wide range of transfection reagents to fulfill the particular needs of transfection and idealize the conditions of cell culture. 

The services segment is anticipated to expand at a CAGR of 12.1% from 2022 to 2030. The growth is attributed to the increasing outsourcing by pharmaceutical and biotech companies to antibody production companies for protein production and expression to support their personalized assay development and discovery of therapeutic antibodies.

Similarly, numerous players are employing strategic initiatives to expand their presence in the market. In August 2022, BioIVT announced the acquisition of Cypex, as the acquired company’s product range of proteins complements BioIVT’s solutions for drug research and development. Furthermore, Cypex’s offerings are developed through patented technology, that allows the expression of human drug-metabolizing enzymes in bacteria, without the need for a major modification to the proteins.

Application Insights

The therapeutic segment dominated the market with over 51.0% in 2021 and is anticipated to register the highest growth rate over the forecast period as protein therapeutics pose numerous advantages over other medications. They are customizable, resulting in a more effective line of treatment and a low probability of side effects. Additionally, it can act as a replacement treatment during the shortage of a functional protein in the body owing to gene deficiency.

The most important driver of this application segment is the increasing participation of companies in developing protein-based therapeutics as the approval time is comparatively shorter and has better patent protection regulation. Both these factors increase the profitability of the pharma and biotech companies and encourage further investment in R&D.

End-user Insights

The pharmaceutical and biotechnological companies segment held the largest revenue share of over 46.0% in 2022 due to the widespread use of cultured cells for the development of therapeutics and personalized medicines. As of 2019, over 170 recombinant proteins are used in medicine across the globe. The segment is driven by the increasing innovative use of proteins in the pharmaceutical industry. For creating a superior value in therapeutic and protein stability, the companies use existing proteins with genetic variants coupled with completely new protein designs.

Contract research organizations are expected to register the fastest growth rate over the forecast period. This can be attributed to the range of specialized services provided by the organizations to the pharma and biopharma companies at considerable pricing, thereby offering a competitive advantage over their competitors. For instance, Charles River Laboratories offers services ranging from construction design to automated protein purification. 

Regional Insights

North America dominated the regional market with a share of over 41.0% in 2022. This major proportion of share can be attributed to the presence of key players in the region, increasing fund flow in R&D, and strong pipelines of biosimilars. It has been observed that collaboration between companies and academic institutions is one of the key strategies employed in the North American region.

Asia Pacific is anticipated to be the fastest-growing region over the forecast period owing to the increasing adoption of protein expression in various applications, particularly in India and China. Additionally, the emerging focus on proteomics and genomics research and increasing initiatives by academic institutions for innovative development in protein therapeutics have offered lucrative growth opportunities to the Asia Pacific market throughout the forecast period.

Some of the prominent players in the Protein Expression Market include:

• Agilent Technologies, Inc.
• Bio-Rad Laboratories
• Thermo Fisher Scientific, Inc.
• Merck Millipore
• New England BioLabs, Inc.
• Promega Corporation
• QIAGEN
• Takara Bio, Inc.
• Oxford Expression Technologies
• Lucigen Corporation

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Protein Expression market

• Expression System Outlook (Revenue, USD Million, 2018 - 2030)
• Prokaryotic
• Mammalian Cell
• Insect Cell
• Yeast
• Others
• Product Outlook (Revenue, USD Million, 2018 - 2030)
• Reagents
• Competent Cells
• Expression Vectors
• Services
• Instruments
• Application Outlook (Revenue, USD Million, 2018 - 2030)
• Therapeutic
• Industrial
• Research
• End-user Outlook (Revenue, USD Million, 2018 - 2030)
• Pharmaceutical & Biotechnological Companies
• Academic Research
• Contract Research Organizations
• Others

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Protein Expression industry analysis from 2022 to 2030 to identify the prevailing Protein Expression industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Protein Expression industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Protein Expression industry trends, key players, market segments, application areas, and market growth strategies.